A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT

University Of Wisconsin-Madison, Madison WI

Investigators

Abstract

The proposed clinical trial will address safety and immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R). It is a pre-surgical phase I dose-escalation study in patients with non-metastatic, node positive, HER2 negative breast cancer that is in remission and defined as no evidence of disease (NED).